These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 1536983)

  • 21. Primary prevention of glucocorticoid-induced osteoporosis with intravenous pamidronate and calcium: a prospective controlled 1-year study comparing a single infusion, an infusion given once every 3 months, and calcium alone.
    Boutsen Y; Jamart J; Esselinckx W; Devogelaer JP
    J Bone Miner Res; 2001 Jan; 16(1):104-12. PubMed ID: 11149473
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pamidronate does not adversely affect bone intrinsic material properties in children with osteogenesis imperfecta.
    Weber M; Roschger P; Fratzl-Zelman N; Schöberl T; Rauch F; Glorieux FH; Fratzl P; Klaushofer K
    Bone; 2006 Sep; 39(3):616-22. PubMed ID: 16644299
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Long-term risedronate treatment normalizes mineralization and continues to preserve trabecular architecture: sequential triple biopsy studies with micro-computed tomography.
    Borah B; Dufresne TE; Ritman EL; Jorgensen SM; Liu S; Chmielewski PA; Phipps RJ; Zhou X; Sibonga JD; Turner RT
    Bone; 2006 Aug; 39(2):345-52. PubMed ID: 16571382
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Collagen maturity, glycation induced-pentosidine, and mineralization are increased following 3-year treatment with incadronate in dogs.
    Saito M; Mori S; Mashiba T; Komatsubara S; Marumo K
    Osteoporos Int; 2008 Sep; 19(9):1343-54. PubMed ID: 18373056
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of strontium ranelate administration on bisphosphonate-altered hydroxyapatite: Matrix incorporation of strontium is accompanied by changes in mineralization and microstructure.
    Busse B; Jobke B; Hahn M; Priemel M; Niecke M; Seitz S; Zustin J; Semler J; Amling M
    Acta Biomater; 2010 Dec; 6(12):4513-21. PubMed ID: 20654744
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The effect of androstenedione/estrone supplementation on cortical and cancellous bone in the young intact female monkey: a model for the effects of polycystic ovarian disease on the skeleton?
    Lundon KM; Jayo MJ; Register TC; Dumitriu M; Grynpas MD
    Osteoporos Int; 2000; 11(9):778-89. PubMed ID: 11210841
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Site-dependent bone mineral density response to oral pamidronate and calcium in postmenopausal osteoporosis: a preliminary report.
    Barreira JC; Messina OD; Maldonado-Cocco JA; Roldan EJ
    Clin Rheumatol; 1997 Jun; 16(4):346-52. PubMed ID: 9259247
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cyclical pamidronate infusions in postmenopausal osteoporosis.
    Peretz A; Body JJ; Dumon JC; Rozenberg S; Hotimski A; Praet JP; Moris M; Ham H; Bergmann P
    Maturitas; 1996 Aug; 25(1):69-75. PubMed ID: 8887311
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Treatment of fibrous dysplasia of bone with intravenous pamidronate: long-term effectiveness and evaluation of predictors of response to treatment.
    Chapurlat RD; Hugueny P; Delmas PD; Meunier PJ
    Bone; 2004 Jul; 35(1):235-42. PubMed ID: 15207763
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of minodronic acid and alendronate on bone remodeling, microdamage accumulation, degree of mineralization and bone mechanical properties in ovariectomized cynomolgus monkeys.
    Yamagami Y; Mashiba T; Iwata K; Tanaka M; Nozaki K; Yamamoto T
    Bone; 2013 May; 54(1):1-7. PubMed ID: 23356990
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Contribution of the intra-specimen variations in tissue mineralization to PTH- and raloxifene-induced changes in stiffness of rat vertebrae.
    Easley SK; Jekir MG; Burghardt AJ; Li M; Keaveny TM
    Bone; 2010 Apr; 46(4):1162-9. PubMed ID: 20034599
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The effects of suppressed bone remodeling by bisphosphonates on microdamage accumulation and degree of mineralization in the cortical bone of dog rib.
    Mashiba T; Mori S; Burr DB; Komatsubara S; Cao Y; Manabe T; Norimatsu H
    J Bone Miner Metab; 2005; 23 Suppl():36-42. PubMed ID: 15984412
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of treatment with ibandronate on bone mass, architecture, biomechanical properties, and bone concentration of ibandronate in ovariectomized aged rats.
    Bauss F; Lalla S; Endele R; Hothorn LA
    J Rheumatol; 2002 Oct; 29(10):2200-8. PubMed ID: 12375334
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of growth hormone and pamidronate on bone blood flow, bone mineral and IGF-I levels in the rat.
    Kapitola J; Zák J; Lacinová Z; Justová V
    Physiol Res; 2000; 49 Suppl 1():S101-6. PubMed ID: 10984078
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of intermittent administration of pamidronate on the mechanical properties of canine cortical and trabecular bone.
    Acito AJ; Kasra M; Lee JM; Grynpas MD
    J Orthop Res; 1994 Sep; 12(5):742-6. PubMed ID: 7931792
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evidence that treatment with risedronate in women with postmenopausal osteoporosis affects bone mineralization and bone volume.
    Fratzl P; Roschger P; Fratzl-Zelman N; Paschalis EP; Phipps R; Klaushofer K
    Calcif Tissue Int; 2007 Aug; 81(2):73-80. PubMed ID: 17612779
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Fluoride effects on bone formation and mineralization are influenced by genetics.
    Mousny M; Omelon S; Wise L; Everett ET; Dumitriu M; Holmyard DP; Banse X; Devogelaer JP; Grynpas MD
    Bone; 2008 Dec; 43(6):1067-74. PubMed ID: 18755305
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Biomechanical effects of the full range of useful doses of (3-amino-1-hydroxypropylidene)-1,1-bisphosphonate (APD) on femur diaphyses and cortical bone tissue in rats.
    Ferretti JL; Cointry G; Capozza R; Montuori E; Roldán E; Pérez Lloret A
    Bone Miner; 1990 Oct; 11(1):111-22. PubMed ID: 2268736
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Experimental effects of olpadronate and pamidronate on bone mass].
    Mondelo N; Parma MD; Peluffo VA; Zanchetta JR; Piccinni E; Montuori E
    Medicina (B Aires); 1997; 57 Suppl 1():17-24. PubMed ID: 9567350
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Combined treatment of growth hormone and the bisphosphonate pamidronate, versus treatment with GH alone, in GH-deficient adults: the effects on renal phosphate handling, bone turnover and bone mineral mass.
    Valk NK; Erdtsieck RJ; Algra D; Lamberts SW; Pols HA
    Clin Endocrinol (Oxf); 1995 Sep; 43(3):317-24. PubMed ID: 7586601
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.